Skip to content

Advertisement

Journal for ImmunoTherapy of Cancer

What do you think about BMC? Take part in

Basic Tumor Immunology

Section edited by Cornelis J.M. Melief, MD, PhD

Tumor antigens, innate and adaptive anti-tumor immune mechanisms, immune regulation, immune response, cancer and inflammation, preclinical models, chemotherapy and radiotherapy interactions/combinations of chemotherapy and radiotherapy, other combination treatments with the anti-tumor immune response, and oncolytic viruses.

Previous Page Page 1 of 2 Next Page
  1. Content type: Research article

    Colorectal cancer is responsible for almost 700,000 deaths annually worldwide. Therapeutic vaccination is a promising alternative to conventional treatment for colorectal cancer, using vaccines to induce targe...

    Authors: Braeden Donaldson, Farah Al-Barwani, Simon J. Pelham, Katie Young, Vernon K. Ward and Sarah L. Young

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:69

    Published on:

  2. Content type: Research article

    The suppressive nature of immune cells in the tumor microenvironment plays a major role in regulating anti-tumor immune responses. Our previous work demonstrated that a soluble factor from tumor cells is able ...

    Authors: Brian T. Maybruck, Lukas W. Pfannenstiel, Marcela Diaz-Montero and Brian R. Gastman

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:65

    Published on:

  3. Content type: Research article

    T-cell checkpoint blockade and MEK inhibitor combinations are under clinical investigation. Despite progress elucidating the immuno-modulatory effects of MEK inhibitors as standalone therapies, the impact of M...

    Authors: Edmund Poon, Stefanie Mullins, Amanda Watkins, Geoffrey S. Williams, Jens-Oliver Koopmann, Gianfranco Di Genova, Marie Cumberbatch, Margaret Veldman-Jones, Shaun E. Grosskurth, Vasu Sah, Alwin Schuller, Corrine Reimer, Simon J. Dovedi, Paul D. Smith, Ross Stewart and Robert W. Wilkinson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:63

    Published on:

  4. Content type: Research article

    We previously demonstrated that in addition to generating an antigen-specific immune response, Listeria monocytogenes (Lm)-based immunotherapy significantly reduces the ratio of regulatory T cells (Tregs)/CD4+ an...

    Authors: Rajeev Shrimali, Shamim Ahmad, Zuzana Berrong, Grigori Okoev, Adelaida Matevosyan, Ghazaleh Shoja E. Razavi, Robert Petit, Seema Gupta, Mikayel Mkrtichyan and Samir N. Khleif

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:64

    Published on:

  5. Content type: Research article

    The expansion of antigen-specific CD8 T cells is important in generating an effective and long-lasting immune response to tumors and viruses. Glucocorticoid-induced tumor necrosis factor receptor family-relate...

    Authors: Nick M. Durham, Nick Holoweckyj, Randall S. MacGill, Kelly McGlinchey, Ching Ching Leow and Scott H. Robbins

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:47

    Published on:

  6. Content type: Research article

    Adoptive cellular therapy (ACT) with cancer antigen-reactive T cells following lymphodepletive pre-conditioning has emerged as a potentially curative therapy for patients with advanced cancers. However, identi...

    Authors: Weiqing Jing, Jill A. Gershan, Grace C. Blitzer, Katie Palen, James Weber, Laura McOlash, Matthew Riese and Bryon D. Johnson

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:51

    Published on:

  7. Content type: Research article

    Clinical success with chimeric antigen receptor (CAR)- based immunotherapy for leukemia has been accompanied by the associated finding that antigen-escape variants of the disease are responsible for relapse. T...

    Authors: Dina Schneider, Ying Xiong, Darong Wu, Volker Nӧlle, Sarah Schmitz, Waleed Haso, Andrew Kaiser, Boro Dropulic and Rimas J. Orentas

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:42

    Published on:

  8. Content type: Research article

    Human γδ T cells expressing Vγ2Vδ2 T cell receptors monitor foreign- and self-prenyl pyrophosphate metabolites in isoprenoid biosynthesis to mediate immunity to microbes and tumors. Adoptive immunotherapy with...

    Authors: Mohanad H. Nada, Hong Wang, Grefachew Workalemahu, Yoshimasa Tanaka and Craig T. Morita

    Citation: Journal for ImmunoTherapy of Cancer 2017 5:9

    Published on:

  9. Content type: Research article

    Although therapeutic cancer vaccines have been mostly disappointing in the clinic, the advent of novel immunotherapies and the future promise of neoantigen-based therapies have created the need for new vaccine...

    Authors: James T. Gordy, Kun Luo, Hong Zhang, Arya Biragyn and Richard B. Markham

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:96

    Published on:

  10. Content type: Research article

    Tumors avoid destruction by cytotoxic T cells (CTL) and natural killer (NK) cells by downregulation of classical human leukocyte antigens (HLA) and overexpression of non-classical HLA. This is the first study ...

    Authors: Debbie M. Ferns, A. Marijne Heeren, Sanne Samuels, Maaike C. G. Bleeker, Tanja D. de Gruijl, Gemma G. Kenter and Ekaterina S. Jordanova

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:78

    Published on:

  11. Content type: Research article

    Future cancer immunotherapies will combine multiple treatments to generate functional immune responses to cancer antigens through synergistic, multi-modal mechanisms. In this study we explored the combination ...

    Authors: Genevieve M. Weir, Olga Hrytsenko, Tara Quinton, Neil L. Berinstein, Marianne M. Stanford and Marc Mansour

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:68

    Published on:

  12. Content type: Research article

    Ovarian cancer (OvCA) tissues show abundant expression of the ectonucleotidases CD39 and CD73 which generate immunomodulatory adenosine, thereby inhibiting cytotoxic lymphocytes. Little, however, is known abou...

    Authors: Itsaso Montalbán del Barrio, Cornelia Penski, Laura Schlahsa, Roland G. Stein, Joachim Diessner, Achim Wöckel, Johannes Dietl, Manfred B. Lutz, Michel Mittelbronn, Jörg Wischhusen and Sebastian F. M. Häusler

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:49

    Published on:

  13. Content type: Research article

    Therapeutic resistance and tumor recurrence are two major hurdles in the treatment of pancreatic ductal adenocarcinoma. Recent findings suggest that both of these attributes are associated with a small subset ...

    Authors: Jason W.-L. Eng, Thomas A. Mace, Rohit Sharma, Danielle Y. F. Twum, Peng Peng, John F. Gibbs, Rosemarie Pitoniak, Chelsey B. Reed, Scott I. Abrams, Elizabeth A. Repasky and Bonnie L. Hylander

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:33

    Published on:

  14. Content type: Research article

    Adoptive T-cell based immunotherapies constitute a promising approach to treat cancer, however, a major problem is to obtain effective and long-lasting anti-tumor responses. Lack of response may be due to insu...

    Authors: Imran Siddiqui, Marco Erreni, Mandy van Brakel, Reno Debets and Paola Allavena

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:21

    Published on:

  15. Content type: Research article

    Lymphodepletion enhances adoptive T cell transfer (ACT) therapy by activating the innate immune system via microbes released from the radiation-injured gut. Microbial components, such as LPS, are key mediators...

    Authors: Michelle H. Nelson, Jacob S. Bowers, Stefanie R. Bailey, Marshall A. Diven, Caroline W. Fugle, Andrew D. M. Kaiser, Claudia Wrzesinski, Bei Liu, Nicholas P. Restifo and Chrystal M. Paulos

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:6

    Published on:

  16. Content type: Research article

    A current focus in cancer treatment is to broaden responses to immunotherapy. One reason these therapies may prove inadequate is that T lymphocytes fail to recognize the tumor due to differences in immunogenic...

    Authors: Katherine Woods, Ashley J. Knights, Matthew Anaka, Ralf B. Schittenhelm, Anthony W. Purcell, Andreas Behren and Jonathan Cebon

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:10

    Published on:

  17. Content type: Research article

    Annexin A2 (ANXA2) is a pleiotropic, calcium-dependent, phospholipid-binding protein with a broad tissue distribution. It can be intracellular, membrane-bound, or secreted, and it exists as a monomer or hetero...

    Authors: Brian M. Andersen, Junzhe Xia, Alan L. Epstein, John R. Ohlfest, Wei Chen, Bruce R. Blazar, Christopher A. Pennell and Michael R. Olin

    Citation: Journal for ImmunoTherapy of Cancer 2016 4:11

    Published on:

  18. Content type: Research article

    Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastas...

    Authors: Anders Olsson, Jessica Nakhlé, Anette Sundstedt, Pascale Plas, Anne-Laure Bauchet, Valérie Pierron, Luce Bruetschy, Adnan Deronic, Marie Törngren, David Liberg, Fabien Schmidlin and Tomas Leanderson

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:53

    Published on:

  19. Content type: Research article

    Adoptive cell transfer of tumor-specific T lymphocytes (T cells) is proving to be an effective strategy for treating established tumors in cancer patients. One method of generating these cells is accomplished ...

    Authors: Joanne A. Hammill, Heather VanSeggelen, Christopher W. Helsen, Galina F. Denisova, Carole Evelegh, Daniela G. M. Tantalo, Jennifer D. Bassett and Jonathan L. Bramson

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:55

    Published on:

  20. Content type: Research article

    Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb is a relat...

    Authors: Venky Ramakrishna, Karuna Sundarapandiyan, Biwei Zhao, Max Bylesjo, Henry C. Marsh and Tibor Keler

    Citation: Journal for ImmunoTherapy of Cancer 2015 3:37

    Published on:

Previous Page Page 1 of 2 Next Page

2016 Journal Metrics

  • Speed
    27 days from submission to first decision
    11 days from acceptance to publication

    Usage 
    358,247 downloads
    1157.0 Usage Factor

    Social Media Impact
    114 mentions

Advertisement